Matos Leandro L, Sanabria Alvaro, Robbins K Thomas, Halmos Gyorgy B, Strojan Primož, Ng Wai Tong, Takes Robert P, Angelos Peter, Piazza Cesare, de Bree Remco, Ronen Ohad, Guntinas-Lichius Orlando, Eisbruch Avraham, Zafereo Mark, Mäkitie Antti A, Shaha Ashok R, Coca-Pelaz Andres, Rinaldo Alessandra, Saba Nabil F, Cohen Oded, Lopez Fernando, Rodrigo Juan P, Silver Carl E, Strandberg Timo E, Kowalski Luiz Paulo, Ferlito Alfio
Department of Head and Neck Surgery, Instituto do Cancer do Estado de São Paulo (ICESP), University of São Paulo Medical School, and Faculdade Israelita de Ciências da Saúde Albert Einstein Medical School, São Paulo, Brazil.
Department of Surgery, School of Medicine, Universidad de Antioquia, Centro de Excelencia en Cirugia de Cabeza y Cuello-CEXCA, Medellin, Colombia.
Adv Ther. 2023 May;40(5):1957-1974. doi: 10.1007/s12325-023-02460-x. Epub 2023 Mar 15.
The projected increase in life expectancy over the next few decades is expected to result in a rise in age-related diseases, including cancer. Head and neck cancer (HNC) is a worldwide health problem with high rates of morbidity and mortality. In this report, we have critically reviewed the literature reporting the management of older patients with HNC. Older adults are more prone to complications and toxicities secondary to HNC treatment, especially those patients who are frail or have comorbidities. Thus, this population should be screened prior to treatment for such predispositions to maximize medical management of comorbidities. Chronologic age itself is not a reason for choosing less intensive treatment for older HNC patients. Whenever possible, also older patients should be treated according to the best standard of care, as nonstandard approaches may result in increased treatment failure rates and mortality. The treatment plan is best established by a multidisciplinary tumor board with shared decision-making with patients and family. Treatment modifications should be considered for those patients who have severe comorbidities, evidence of frailty (low performance status), or low performance status or those who refuse the recommendations of the tumor board.
预计未来几十年预期寿命的增长将导致包括癌症在内的与年龄相关疾病的增加。头颈癌(HNC)是一个全球性的健康问题,发病率和死亡率都很高。在本报告中,我们严格审查了有关老年头颈癌患者管理的文献。老年人更容易因头颈癌治疗而出现并发症和毒性反应,尤其是那些身体虚弱或患有合并症的患者。因此,在治疗前应对该人群进行此类易感性筛查,以最大限度地对合并症进行医疗管理。实际年龄本身并不是为老年头颈癌患者选择强度较低治疗的理由。只要有可能,老年患者也应按照最佳护理标准进行治疗,因为非标准方法可能会导致治疗失败率和死亡率上升。治疗方案最好由多学科肿瘤委员会制定,并与患者及其家属共同决策。对于那些患有严重合并症、有身体虚弱迹象(低体能状态)或低体能状态的患者,或那些拒绝肿瘤委员会建议的患者,应考虑调整治疗方案。